NEW YORK, September 22, 2016 /PRNewswire/ --
Transparency Market Research published a report on the global
biotechnology market and claiming that this vibrant market is
expected to grow at an average annual growth rate of CAGR rate of
11.6% by the end of 2017. The data provided indicates that in 2011,
the market was valued at roughly $216.5
billion, yet major changes in the way the industry operates
and innovative developments in the sector, have pushed values to
reach $414.5 billion by the end of
2017. Allergan PLC (NYSE: AGN), Tobira
Therapeutics, Inc. (NASDAQ: TBRA), MabVax Therapeutics
Holdings, Inc. (NASDAQ: MBVX), Aerie Pharmaceuticals
Inc. (NASDAQ: AERI), Puma Biotechnology Inc. (NYSE:
PBYI).
This week, Allergan PLC (NYSE: AGN) announced the
acquisition of biopharmaceutical company, Tobira Therapeutics,
Inc. (NASDAQ: TBRA) in a deal worth as much as $1.7 billion, a move to gain more exposure in the
liver diseases therapies area. Allergan has agreed to make a direct
payment of $28.35 a share in cash and
as much as $49.84 a share based on
the successful completion of certain developments, regulatory and
commercial milestones. Even if the company does not reach certain
developments, the offer still represents a 498 percent premium to
Tobira's closing price of $4.74 a
share earlier in the week. Shares of Tobira skyrocketed over 700
percent after the announcement.
Another small cap company focused on the development of
antibody-based products to address unmet medical needs in the
treatment of cancer, MabVax Therapeutics Holdings, Inc.
(NASDAQ: MBVX), has released the current progress of its antibody
development program, HuMab-5B1. MabVax worked on two clinical
trials this year with therapeutic agent (MVT-5873), a new
generation PET imaging product (MVT-2163), and a radio
immunotherapy agent (MVT-1075), and plans on filing an
Investigational New Drug with the U.S. Food and Drug Administration
later this year. On August
17th, MabVax Therapeutics reached a corporate
milestone by successfully completing their uplisting and started to
trade on NASDAQ exchange.
MabVax Therapeutics Holdings, Inc. (MBVX) Phase I trial
for MVT-5873 began in the first quarter of this year to evaluate
the safety, tolerability and pharmacokinetics as a single agent or
in combination with a standard of care chemotherapy. The trial is
currently examining patients with metastatic pancreatic cancer. The
MVT-2163 is a positron emission tomography PET imaging agent. The
Phase I trial began in the second quarter of this year. In
preclinical models the use of the imaging agent resulted in
high-resolution images of tumors in xenograft animal models, and
now being tested on humans in hopes to help with diagnosis,
monitoring, and assessment of patients with pancreatic cancer.
MabVax's collaborations with key cancer research centers and
oncology companies include the Memorial Sloan Kettering Cancer
Center, Rockefeller University and
Heidelberg Pharma.
Pharmaceutical company, Aerie Pharmaceuticals Inc.
(NASDAQ: AERI) continues to rally after many Wall Street investment
research firms upgraded the company to a "buy". Aerie has disclosed
effective phase 3 trial results for its glaucoma drug, Roclatan.
Roclatan is capable of reducing intraocular pressure (IOP) in
patients who has glaucoma or ocular hypertension. Aerie is a
clinical-stage pharmaceutical company mainly focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with diseases of the eye.
Ever since the release of the reports, shares soared over 50
percent and peaked all-time highs at $38.74.
Shares of Puma Biotechnology Inc. (NYSE: PBYI) surged
over 13.5 percent after the U.S. Food and Drug Administration
accepted its New Drug Application to treat breast cancer, the PB272
(Neratinib). Neratinib allows the company to treat extended
adjuvant patients with early stage HER2-overexpressed breast cancer
who have also had prior adjuvant breast cancer therapy with
Herceptin (trastuzumab). Puma Biotechnology is a biopharmaceutical
company devoted to the acquisition and development of novel
therapeutics for the treatment of cancer.
For "The Latest Buzz in Financial News", SIGN UP & Visit:
http://www.FinancialBuzz.com
Follow us on Twitter for real time Financial News Updates:
https://twitter.com/financialbuzz
Facebook Like Us to receive live feeds:
https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web
portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth
broadcasts on Stock News, Market Analysis and Company Interviews. A
pioneer in the financially driven digital space, video production
and integration of social media, FinancialBuzz.com creates 100%
unique original content. FinancialBuzz.com also provides financial
news PR branding, marketing and advertising for third parties for
disseminating news and original content through our unique media
platform that includes Newswire Delivery, Digital Advertising,
Social Media Relations, Video Production, Broadcasting, and
Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or
advisor, investment advisor or broker-dealer and do not undertake
any activities that would require such registration. The
information provided on http://www.FinancialBuzz.com (the "Site")
is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content),
FinancialBuzz.com, a financial news media and pr marketing firm
enters into service agreements with the companies which are the
subject to the articles posted on the Site for advertising such
companies. Financialbuzz.com has been compensated twelve thousand dollars for financial news pr
services by a non-affiliated third party. We are not an independent
news media provider and therefore do not represent or warrant that
the information posted on the Site is accurate, unbiased or
complete. FinancialBuzz.com receives fees for producing and
presenting the high quality and sophisticated content on this site
along with other financial news pr media services. Our fees may be
either a flat cash sum or negotiated number of securities of the
companies featured on this site, or a combination thereof.
The securities are commonly paid in segments, of which a
portion is received upon engagement and the balance is paid on or
near the conclusion of the engagement. FinancialBuzz.com does not
undertake to update any of the information on the Site or continue
to post information about any companies the information contained
herein is not intended to be used as the basis for investment
decisions and should not be considered as investment advice or a
recommendation. The information contained herein is not an offer or
solicitation to buy, hold or sell any security.
FinancialBuzz.com, members and affiliates are not responsible
for any gains or losses that result from the opinions expressed on
the Site, company profiles, quotations or in other materials or
presentations that it publishes electronically or in print.
Investors accept full responsibility for any and all of their
investment decisions based on their own independent research and
evaluation of their own investment goals, risk tolerance, and
financial condition. FinancialBuzz.com. By accessing this website
and any pages thereof, you agree to be bound by the Terms of Use
and Privacy Policy, as may be amended from time to time. None of
the content issued by FinancialBuzz.com constitutes a
recommendation for any investor to purchase, hold or sell any
particular security, pursue a particular investment strategy or
that any security is suitable for any investor. This publication is
provided by FinancialBuzz.com. Each investor is solely responsible
for determining whether a particular security or investment
strategy is suitable based on their objectives, other securities
holdings, financial situation needs, and tax status. You agree to
consult with your investment advisor, tax and legal consultant
before making any investment decisions. We make no representations
as to the completeness, accuracy or timeless of the material
provided. All materials are subject to change without notice.
Information is obtained from sources believed to be reliable, but
its accuracy and completeness are not guaranteed. For our full
disclaimer, disclosure and Terms of Use.
Please visit: http://www.financialbuzz.com
For further information:
Media Contact: Danny
Abramov, info@financialbuzz.com, +1-877-601-1879
SOURCE FinancialBuzz.com